KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III EGFR-mutated NSCLC: LAURA China cohort.

Xiaorong Dong, Hong Jian, Meijuan Huang, Shuanghu Yuan, Zhengfei Zhu, Lin Wu, Ming Chen, Nan Bi, Yi Pan, Yingyi Wang, Dongqing Lv, Elena Armenteros Monterroso, Xiangning Huang, Rui Mao, Wei Fu, Yi Zhao, Shun Lu

Lung Cancer 215 109343

PMID41785639
PMCID-
DOI10.1016/j.lungcan.2026.109343
发表日期2026-03-05
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: In the phase III LAURA study, osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor demonstrated statistically significant improvement in progression-free survival (PFS) versus placebo in patients with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC) without progression during/after definitive chemoradiotherapy (CRT); PFS hazard ratio 0.16; 95 % confidence interval (CI): 0.10-0.24; p < 0.001. Here we report pre-specified exploratory efficacy and safety analyses in the LAURA China cohort (which was a stratification factor). METHODS: Adults with unresectable stage III EGFR-mutated (exon 19 deletion/L858R) NSCLC without progression during/after CRT were randomized 2:1 to receive osimertinib 80 mg once daily or placebo until disease progression (per Response Evaluation Criteria in Solid Tumours version 1.1) or discontinuation. The primary endpoint was PFS by blinded independent central review (BICR). Secondary endpoints included overall survival, objective response rate (ORR), duration of response and safety. RESULTS: Of 216 patients randomized globally, 40 (19 %) were enrolled in mainland China, comprising the China cohort (osimertinib n = 27; placebo n = 13). Baseline characteristics were generally well-balanced between treatment arms. Median (95 % CI) BICR-assessed PFS was not reached (17.4-not calculable) versus 3.7 months (1.8-7.7) with osimertinib versus placebo, respectively. ORR (95 % CI) was 63 % (42-81) and 15 % (2-45), respectively. The majority of adverse events (AEs) were grade 1 or 2 in severity and did not lead to treatment discontinuation. No AEs led to dose reductions or death. CONCLUSIONS: Osimertinib after definitive CRT demonstrated PFS benefit over placebo and a manageable safety profile in the China cohort, consistent with findings in the global LAURA population. The results support the use of osimertinib after definitive CRT as the new standard of care, globally and in China, for patients with unresectable stage III EGFR-mutated NSCLC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。